GlobeNewswire by notified

[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023

Share
  • Christoph Franz has decided not to seek re-election to the Board of Directors at the Annual General Meeting (AGM) in March 2023
  • The Board of Directors intends to propose Severin Schwan as new Chairman at the Annual General Meeting
  • The Board of Directors has appointed Thomas Schinecker as the new Roche CEO effective 15 March 2023

Basel, 21 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Christoph Franz has decided not to seek re-election to the Board of Directors at the AGM in March 2023. The Board of Directors intends to propose Severin Schwan as new Chairman at the AGM and has appointed Thomas Schinecker as new Roche CEO effective 15 March 2023.

Christoph Franz was elected to the Roche Board of Directors in 2011 and has served as its Chairman since 2014: ”After serving twelve years on the Board of Directors, nine of which as Chairman, I have decided not to seek re-election to the Board next year. We have achieved many important milestones and with the conclusion of Roche's 125th anniversary, it is now the right time for a change in leadership. I am proud of the significant contributions Roche has made in fighting the pandemic during the last two and a half years. I am also pleased that we could secure long term stability in our shareholder structure with the repurchase of Roche shares from Novartis. With the strong pipelines of innovative products in both our Pharma and Diagnostic businesses, we are set for continued growth in the future.”

The Roche Board of Directors will propose Severin Schwan as new Chairman at the AGM on 14 March 2023. Severin Schwan has been a member of the Corporate Executive Committee since 2006 and has served as CEO of the company since 2008. He has been a member of the Roche Board of Directors since 2013. Severin Schwan: ”I have very much appreciated the close and trusting collaboration with Christoph and would like to thank him. I am honoured to stand for the position of Chairman of the Roche Board of Directors and will continue to dedicate all my efforts to the future of this company.”

André Hoffmann, Vice-Chairman of the Board of Directors and representative of the Oeri and Hoffmann shareholder group with pooled voting rights: “Thanks to Christoph’s long term strategic vision, he has steered our company confidently and successfully through challenging times. Roche’s continued success is in no small part due to his personal contributions. I would like to thank him sincerely, also in the name of our families. As in the past, we are able to secure the succession to the Chairman and CEO roles with excellent leaders from within Roche. This is a great quality of our company.”

Effective 15 March 2023, the Board of Directors has appointed Thomas Schinecker, currently CEO of the Diagnostics Division, as CEO of Roche succeeding Severin Schwan. Thomas Schinecker holds a PhD in Molecular Biology and has been working for Roche in different leadership positions since 2003. He became CEO of the Diagnostics Division and a member of the Corporate Executive Committee in August 2019.

Severin Schwan: ”I am very pleased that the Board has appointed Thomas as the new Roche CEO. He is a highly qualified successor who has been working for Roche in leadership positions around the globe for twenty years. Thomas successfully set up our Diagnostics Division for the future. Under his leadership our Diagnostics organisation also made considerable contributions in fighting the COVID-19 pandemic.”

Thomas Schinecker: “I am deeply honoured by the Board’s decision and the trust placed in me. I am delighted to carry on working closely with Roche colleagues and the Corporate Executive Committee. Like we’ve done for the last 125 years, I am excited about the future innovations we will bring to patients around the globe.”

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 61 687 41 47



Nathalie Altermatt
Phone: +41 61 687 43 05
KarstenKleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
SileiaUrech
Phone: +41 79 935 81 48

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ObsEva Files Second Quarter 2022 Financial Statements17.8.2022 22:01:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – August 17, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published its Second Quarter 2022 Financial Statements. The Second Quarter 2022 Financial Statements may be found on the financial section of the Company’s website, here or directly via the link here. About ObsEva ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical pipeline with development programs focused on new therapies for the treatment of preterm labor and improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “O

GOGL - Invitation to presentation of Q2 2022 Results17.8.2022 19:30:59 CEST | Press release

Golden Ocean Group Limited (the “Company) will publish its financial results for the second quarter of 2022 on Thursday August 25, 2022. In connection with the release, a conference call and webcast will be held as described below: Conference call and webcast A conference call will be held at 4:00 P.M. CET (10:00 A.M. New York Time) on Thursday August 25, 2022. The presentation will be available for download from the Investor Relations section at www.goldenocean.bm (under "Presentations") prior to the conference call/webcast. In order to listen to the presentation you may do one of the following: a. Webcast Visit the Investor Relations section of the Company’s website at www.goldenocean.bm and click on the link to “Financial Calendar and Webcast”, or access directly via the webcast link below. GOGL Q2 2022 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered. GOGL Q2 2022

Changes in Nokia Corporation's own shares17.8.2022 18:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 17 August 2022 at 19:30 EEST Changes in Nokia Corporation's own shares Espoo, Finland – A total of 189 403 Nokia shares (NOKIA) held by the company were today transferred without consideration to participants of Nokia's equity-based incentive plan in accordance with the rules of the plan. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plan as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 79 311 737. About Nokia At Nokia, we create technology that helps the world act together. As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs. Adhering to the highest standards of integrity and security, w

Spryker Recognized as a Visionary in 2022 Magic Quadrant™ For Digital Commerce17.8.2022 18:00:00 CEST | Press release

BERLIN and NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Spryker, a leading digital commerce platform for Sophisticated Commerce use cases in B2B, Enterprise Marketplaces, IoT and Unified Commerce, has been recognized by Gartner® as a Visionary in the 2022 Magic Quadrant™ for Digital Commerce. It is Spryker's third consecutive inclusion in the Gartner® Magic Quadrant™ for Digital Commerce. “At Spryker, our goal is to enable digital innovation and differentiation with our composable platform designed specifically for sophisticated transactional business models. We believe being recognized for the second time as a Visionary validates our continued dedication to empowering companies to grow, innovate, and differentiate,” said Boris Lokschin, Co-Founder and CEO at Spryker. “This year we launched our App Composition Platform as the latest stage in our commitment to delivering true composability. This first of its kind platform is why we feel Spryker continues to be recognized in the market. W

Nextensa NV/SA : Half-Year Financial Report 202217.8.2022 17:40:00 CEST | Press release

HALF-YEAR FINANCIAL REPORT 2022 Regulated information Brussels, 17 August 2022 5:40 PM CEST For the first half-year of the financial year 2022 we record the following key data: • The rental income increased by € 3.0 million compared to June last year and now amounts to € 33.2 million • The financial debt ratio has decreased from 48.56% at the end of 2021 to 46.31% on 30 June 2022, in line with the predefined plan • The occupancy rate increased and is now 90.30% compared to 89.09% at the end of 2021 • The extension of the Shopping center Knauf Schmiede welcomes its first shops • The Park Lane phase II project at Tour & Taxis has been launched with a successful reservation of 50% of the apartments of the first section • The construction works on The Emerald office building (7,000 m2) started on Cloche d’Or, a new urban district in the southern outskirts of Luxembourg City Attachment SEMI-AR_2022_ENG_final